CDMO opportunities center on outsourcing, biologics, advanced therapies, early-stage partnerships, AI-enabled processes and end-to-end services amid capacity constraints.
Healthcare Contract Development And Manufacturing Organization Mark
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) — The “Healthcare CDMO – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
Healthcare CDMO Market to Reach USD 576.26 Billion by 2031, Expanding at a 9.66% CAGR
The global healthcare contract development and manufacturing organization (CDMO) market is estimated to reach USD 363.21 billion in 2026, up from USD 331.22 billion in 2025. The market is projected to grow at a compound annual growth rate of 9.66% from 2026 to 2031, reaching USD 576.26 billion by the end of the forecast period.
Healthcare CDMO market growth is being supported by increased pharmaceutical outsourcing, expanding biologics pipelines, rising demand for advanced therapies, and the growing complexity of drug development and manufacturing. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to improve operational flexibility, reduce fixed-asset exposure, accelerate development timelines, and focus internal resources on research and product commercialization.
Pharmaceutical Outsourcing Becomes a Core Growth Strategy
Approximately 86.9% of drug originators outsource at least one manufacturing activity, highlighting the pharmaceutical industry’s shift toward external development and production partnerships. Portfolio simplification allows sponsors to direct more capital toward drug discovery while transferring manufacturing infrastructure requirements and operational risks to specialized providers.
Major transactions also demonstrate the industry’s focus on high-value biologics capacity. Lonza’s USD 1.2 billion acquisition of a manufacturing facility in Vacaville, alongside the divestment of its capsules business, reflects this strategic transition. Large pharmaceutical companies are also reassessing small-molecule manufacturing assets as they prioritize first-in-class biologics, messenger RNA platforms, and other complex modalities.
These trends support multiyear service agreements that give healthcare CDMOs greater production visibility while creating opportunities to provide analytical testing, regulatory support, formulation development, packaging, and fill-finish services.
Biologics and Advanced Therapies Accelerate Demand
Monoclonal antibodies, antibody-drug conjugates, cell therapies, and gene therapies require specialized production environments, containment systems, technical expertise, and highly coordinated supply chains. The significant capital requirements associated with viral vector manufacturing, high-potency production lines, and segregated facilities are encouraging sponsors to engage CDMOs earlier in the development process.
The U.S. Food and Drug Administration’s Advanced Manufacturing Technologies Designation Program, finalized in 2025, is expected to encourage the adoption of innovative production methods and reduce regulatory uncertainty for qualifying manufacturing platforms. As approvals of CAR-T, gene-edited, and other personalized therapies increase, demand is also rising for small-batch manufacturing, flexible cleanrooms, just-in-time production, and integrated logistics designed to protect sensitive materials.
Capacity Constraints Create Opportunities and Scheduling Risks
Despite ongoing investments, specialized biologics and antibody-drug conjugate capacity remains constrained. Allocation windows for some ADC manufacturing suites can extend from 24 to 36 months, requiring sponsors to reserve capacity well before receiving Phase I clinical results.
Daiichi Sankyo’s planned USD 1 billion ADC facility in Germany and AstraZeneca’s USD 1.5 billion manufacturing project in Singapore are expected to add capacity, although their impact may not be fully realized until 2028 or later. Limited availability is strengthening the position of integrated CDMOs and increasing reservation fees. At the same time, pharmaceutical companies are adopting dual-sourcing strategies and retaining pilot-scale capabilities to reduce scheduling and supply risks.
Additional factors influencing the healthcare CDMO market include:
- Increasing molecule complexity and demand for end-to-end CDMO services
- AI-driven process optimization that shortens technology-transfer timelines
- Stringent regulatory compliance requirements and audit-related risks
Contract Manufacturing Maintains Market Leadership
Contract manufacturing accounted for 73.45% of the healthcare CDMO market in 2025. The segment includes small-molecule active pharmaceutical ingredients, large-scale monoclonal antibody production, sterile injectables, and other finished dosage forms. Demand for high-potency and cytotoxic manufacturing capacity is supporting higher pricing and multiyear take-or-pay agreements, while commoditized oral solid dosage manufacturing continues to provide stable production-line utilization despite pricing pressure.
Contract development services are forecast to expand at a 10.44% CAGR through 2031. Growth is being driven by earlier CDMO involvement in pre-formulation, formulation development, process characterization, analytical testing, and regulatory dossier preparation. Sponsors increasingly prefer a continuous development-to-commercialization model that reduces repeated validation activities and simplifies technology transfer.
Commercial and post-approval programs represented 39.35% of the market in 2025, providing predictable revenue linked to approved therapies. Formulation improvements, new dosage strengths, and other lifecycle-management activities are expected to sustain demand, while high-margin biologics help offset pricing pressure associated with mature products.
Phase I services are projected to record a 10.78% CAGR through 2031. Emerging therapeutic modalities require specialized toxicology batches, flexible manufacturing environments, and expertise in viral vector production and mRNA encapsulation. Early CDMO engagement can extend contract duration and position providers to support subsequent clinical phases and commercial manufacturing.
North America Leads as Asia-Pacific Records the Fastest Growth
North America generated 41.75% of global healthcare CDMO market revenue in 2025. The region benefits from established regulatory expertise, advanced cold-chain infrastructure, major pharmaceutical headquarters, and proximity to leading biotechnology innovation hubs. New capacity investments in Syracuse and Kentucky are targeting high-potency products and sterile injectables, reinforcing the region’s focus on complex biologics.
Asia-Pacific is forecast to grow at an 11.57% CAGR through 2031, supported by manufacturing incentives and capacity expansion in China, Singapore, and South Korea. Samsung Biologics added 360,000 liters of production capacity across Plants 4 and 5 and secured a USD 1.4 billion multiproduct agreement in early 2025. Continued alignment with International Council for Harmonisation guidelines is also improving sponsor confidence across the region.
Europe remains an important center for high-value biologics production, supported by established quality systems and favorable research incentives. Switzerland, Ireland, and Germany are key manufacturing locations, while Eastern Europe provides competitively priced oral dosage and sterile packaging services. South America, the Middle East, and Africa currently hold smaller market shares but are attracting investment as pharmaceutical companies diversify supply chains and strengthen regional manufacturing resilience.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Mainstream outsourcing to focus on core competencies
4.2.2 Growth in biologics & advanced therapies
4.2.3 Increasing molecule complexity demanding end-to-end CDMOs
4.2.4 AI-driven process optimisation slashing tech-transfer timelines
4.2.5 Single-use & continuous manufacturing boosting agile mid-tier CDMOs
4.2.6 Government incentives for GMP capacity across emerging Asia
4.3 Market Restraints
4.3.1 Capacity constraints & long CDMO lead-times
4.3.2 Stringent compliance / audit failures
4.3.3 Sustainability mandates raising green-capex
4.3.4 Talent gaps in high-potency API engineering
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Service Type
5.1.1 Contract Development
5.1.1.1 Pre-formulation & Formulation Development
5.1.1.2 Process Development & Optimisation
5.1.1.3 Analytical, Stability & Release Testing
5.1.2 Contract Manufacturing
5.1.2.1 API Manufacturing
5.1.2.1.1 Small-molecule APIs
5.1.2.1.1.1 Monoclonal Antibodies
5.1.2.1.2 Large-molecule / Biologic APIs
5.1.2.1.2.1 Recombinant Proteins
5.1.2.2 Finished Dosage Formulation
5.1.2.2.1 Vaccines
5.1.2.2.2 Oral Solids (Tablets, Capsules)
5.1.2.2.2.1 Cell & Gene Therapies
5.1.2.2.3 Sterile Injectables / Fill-Finish
5.1.2.2.4 Topicals & Semi-solids
5.1.2.2.5 Other Dosage Forms
5.1.2.3 Packaging & Serialization Services
5.1.2.4 Medical Devices
5.1.2.4.1 Class I
5.1.2.4.2 Class II
5.1.2.4.3 Class III
5.2 By Therapeutic Area
5.2.1 Oncology
5.2.2 Cardiovascular
5.2.3 Infectious Diseases
5.2.4 Neurology / CNS
5.2.5 Auto-immune & Inflammatory
5.2.6 Metabolic Disorders (Diabetes, Obesity)
5.2.7 Rare & Orphan Diseases
5.2.8 Other Therapeutic Areas
5.3 By Development Phase
5.3.1 Pre-clinical
5.3.2 Phase I
5.3.3 Phase II
5.3.4 Phase III
5.3.5 Commercial / Post-Approval
5.4 By End User
5.4.1 Big / Large Pharmaceutical Companies
5.4.2 Emerging & Virtual Biotech Firms
5.4.3 Generic Drug Manufacturers
5.4.4 Medical-Device & Combination-Product Firms
5.4.5 Academic, Government & Non-Profit Sponsors
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 South America
5.5.4.1 Brazil
5.5.4.2 Argentina
5.5.4.3 Rest of South America
5.5.5 Middle East and Africa
5.5.5.1 GCC
5.5.5.2 South Africa
5.5.5.3 Rest of Middle East and Africa
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Catalent, Inc.
6.3.2 Lonza Group AG
6.3.3 Thermo Fisher Scientific Inc.
6.3.4 Samsung Biologics Co., Ltd.
6.3.5 WuXi AppTec Co., Ltd.
6.3.6 FUJIFILM Holdings Corporation
6.3.7 Baxter International Inc.
6.3.8 Cambrex Corporation
6.3.9 PCI Pharma Services (PCI Services LLC)
6.3.10 Recipharm AB
6.3.11 AGC Inc.
6.3.12 Jubilant Pharmova Limited
6.3.13 Piramal Pharma Limited
6.3.14 AbbVie Inc.
6.3.15 C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim)
6.3.16 Vetter Pharma-Fertigung GmbH & Co. KG
6.3.17 Delpharm SAS
6.3.18 Fareva S.A.
6.3.19 Siegfried Holding AG
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/9y43qi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Healthcare Contract Development And Manufacturing Organization Mark
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
